This analysis examines the market position and future outlook for MedImmune. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with global forecasts for key drugs to 2010.
This analysis examines the market position and future outlook for MedImmune. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with global forecasts for key drugs to 2010. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Key reasons to read this report
Assess the impact of the termination of FluMist's co-promotion with Wyeth on MedImmune's future performance
Benchmark MedImmune's performance against key rivals in the biotechnology sector
Understand how cash generated from Synagis could be invested to expand the company's weak late stage pipeline
This analysis examines the market position and future outlook for MedImmune. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with global forecasts for key drugs to 2010. 